Theragenics Corporation^® TGX (the “Company”), a medical device
company serving the surgical products and prostate cancer treatment markets,
announced today that it has signed a definitive merger agreement pursuant to
which a newly formed affiliate (the “Purchaser”) of Juniper Investment
Company, LLC will acquire all of the outstanding common stock of the Company
for $2.20 per share in cash.
The Board of Directors of the Company unanimously approved the merger
agreement and the transactions contemplated thereby. The merger agreement
permits the Company to solicit competing offers from credible and bona fide
third parties through September 6, 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in